Clinical Trial Update: A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

View source ↗

Summary

A completed study evaluating readiness to self-inject and adherence to Copaxone therapy in people with multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Neuroscience, Inc. | Conditions: Multiple Sclerosis | Status: COMPLETED